Study | Mulligan et al. [10] | Terragna et al. [2] |
---|---|---|
Treatment | Bortezomib | VTD |
Number of Samples | 169 | 118 |
Number of Probes | 22,283 | 54,677 |
Patients Population | Relapsed MM | New-Diagnosis |
Progressive Disease (PD) | Stable Disease (SD) | |
13 (7.70%) | 7 (5.93%) | |
No Change (NC) | Partial Response (PR) | |
60 (35.50%) | 42 (35.59%) | |
Minimal Response (MR) | Very good partial response (VGPR) | |
12 (7.10%) | 40 (33.90%) | |
Partial Response (PR) | near Complete Response (nCR) | |
43 (25.44%) | 14 (11.87%) | |
Complete Response (CR) | Complete Response (CR) | |
41 (24.26%) | 15 (12.71%) |